Collegium Pharmaceutical, Inc. (COLL)

NASDAQ: COLL · IEX Real-Time Price · USD
16.02
+0.18 (1.14%)
At close: Sep 30, 2022 4:00 PM
16.82
+0.80 (4.99%)
After-hours: Sep 30, 2022 5:52 PM EDT
1.14%
Market Cap 546.70M
Revenue (ttm) 313.51M
Net Income (ttm) -35.25M
Shares Out 34.13M
EPS (ttm) 1.11
PE Ratio 14.43
Forward PE 3.28
Dividend n/a
Ex-Dividend Date n/a
Volume 249,381
Open 15.95
Previous Close 15.84
Day's Range 15.84 - 16.66
52-Week Range 14.04 - 22.89
Beta 0.85
Analysts Buy
Price Target 33.46 (+108.9%)
Earnings Date Nov 2, 2022

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Colle... [Read more...]

Industry Pharmaceuticals
IPO Date May 7, 2015
CEO Joseph Ciaffoni
Employees 152
Stock Exchange NASDAQ
Ticker Symbol COLL
Full Company Profile

Financial Performance

In 2021, COLL's revenue was $276.87 million, a decrease of -10.69% compared to the previous year's $310.02 million. Earnings were $71.52 million, an increase of 167.33%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 33.46, which is an increase of 108.86% from the latest price.

Price Target
$33.46
(108.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Collegium Reports Second Quarter 2022 Financial Results

– Generated Record Net Revenue of $123.5 Million –

1 month ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second qua...

2 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

7 Micro-Cap Stocks to Take a Chance on Now

Some very small stocks, micro-cap stocks, have good value and are overlooked and should be considered by investors to buy today. The post 7 Micro-Cap Stocks to Take a Chance on Now appeared first on Inv...

Other symbols: AOSLDASHMYEPLABSPTN
3 months ago - InvestorPlace

Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Collegium Reports First Quarter 2022 Financial Results

- Generated Net Revenue of $83.8 Million -

4 months ago - GlobeNewsWire

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a ...

5 months ago - GlobeNewsWire

Collegium to Participate in Upcoming Needham Healthcare Conference

STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will particip...

5 months ago - GlobeNewsWire

COLL or ZTS: Which Is the Better Value Stock Right Now?

COLL vs. ZTS: Which Stock Is the Better Value Option?

Other symbols: ZTS
5 months ago - Zacks Investment Research

Why Collegium Pharmaceutical's Shares Are Trading Higher Today

Collegium Pharmaceutical Inc (NASDAQ: COLL) updated financial guidance for FY22 to include the expected impact of the BioDelivery Sciences International Inc (BDSI) acquisition.  "Near-term, we are laser...

5 months ago - Benzinga

Collegium Provides 2022 Financial Guidance

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million –

5 months ago - GlobeNewsWire

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related ...

6 months ago - GlobeNewsWire

Collegium Completes the Acquisition of BDSI

STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences Internation...

6 months ago - GlobeNewsWire

New Strong Buy Stocks for March 3rd

ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.

Other symbols: ACGLACLSSAHTGH
6 months ago - Zacks Investment Research

Can Collegium Pharmaceutical (COLL) Climb 30% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 29.9% in Collegium Pharmaceutical (COLL). While the effectiveness of this highly sought-after metric is questiona...

7 months ago - Zacks Investment Research

Collegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -170.19% and 66.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...

7 months ago - Zacks Investment Research

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

– BDSI Acquisition Expected to Close Late Q1 2022 –

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc...

Other symbols: BDSI
7 months ago - PRNewsWire

Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal

Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approxim...

Other symbols: BDSI
7 months ago - Benzinga

Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million -

7 months ago - GlobeNewsWire

Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results

STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, Februar...

7 months ago - GlobeNewsWire

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

STOUGHTON, Mass., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...

9 months ago - GlobeNewsWire